<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Schmiegelow, K.</title>
    <link>http://repub.eur.nl/res/aut/23222/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>The controversy of varicella vaccination in children with acute lymphoblastic leukemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/31936/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Standardized MRD quantification in European all trials: Proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 (Article)</title>
      <link>http://repub.eur.nl/res/pub/28078/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms complete MRD response, MRD persistence and MRD reappearance. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. </description>
    </item> <item>
      <title>Editorial: Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000) (Article)</title>
      <link>http://repub.eur.nl/res/pub/19525/</link>
      <pubDate>2010-02-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>T-cell receptor Vβ CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/29859/</link>
      <pubDate>2008-06-01T00:00:00Z</pubDate>
      <description>(Very) severe acquired aplastic anemia ((v)SAA) and myelodysplastic syndrome (MDS) are rare diseases in childhood. (V)SAA is a bone marrow (BM) failure syndrome characterized by immune-mediated destruction of hematopoietic progenitors. MDS is a malignant clonal stem cell disorder, of which the hypoplastic variant is, in case of absence of a cytogenetic clone, difficult to separate from (v)SAA. Recently, studies provided a molecular signature of autoimmunity in adult (v)SAA, by showing oligoclonality based on the length of the TCR Vβ CDR3 region. We investigated retrospectively the frequency and the discriminative value of TCR Vβ CDR3 oligoclonality in pediatric (v)SAA and MDS patients. Peripheral blood (PB) and/or BM mononuclear cell samples of pediatric patients with (v)SAA (n=38), refractory cytopenia (MDS-RC) (n=28) and 18 controls were analysed via TCR Vβ heteroduplex PCR analysis of extracted RNA. A skewed TCR Vβ CDR3 repertoire was found in 21/38 (v)SAA and in 17/28 RC patients in contrast to 2/18 in the control group. These data suggest an overlapping group of RC and SAA patients that may share a common immune-mediated pathogenesis. Prospective studies are required to establish the clinical value of TCR Vβ CDR3 repertoire analysis to predict the clinical response in these patients.</description>
    </item>
  </channel>
</rss>